Company intelligence / Profile preview

Cambridge Biotechnology Ltd.

Cambridge, England, United Kingdomceb.cam.ac.uk ↗

Ownership: Private
Development stage: Phase 1

Overview

Cambridge Biotechnology Ltd. was a UK-based biotech company specializing in early-stage drug discovery, leveraging expertise from former Pfizer/Parke-Davis scientists. It developed proprietary platforms for identifying small molecule leads but did not advance any major programs into late-stage clinical development before being acquired by Biovitrum AB. The company was eventually divested and is no longer independently active.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ABO-101

Phase 1/2

Indications: Primary hyperoxaluria type 1

Beyond the preview

Go deeper on Cambridge Biotechnology Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cambridge Biotechnology Ltd..

Explore the full profile